Basal cell carcinoma (BCC) is the most common cutaneous malignancy, comprising nearly 80% of non-melanoma skin cancers. Despite its typically slow growth and low metastatic potential, BCC demonstrates a locally aggressive behavior capable of causing substantial tissue destruction if not promptly addressed. Lower eyelid is frequent site of involvement, representing a unique therapeutic challenge due to its intricate anatomical architecture and the critical balance between its protective ocular function and aesthetic significance. Surgical management in this region demands precise oncologic excision combined with meticulous reconstructive planning to preserve eyelid function and facial harmony.
Juan et al. (Wed,) studied this question.